OA11733A - Combination chemotherapy. - Google Patents
Combination chemotherapy. Download PDFInfo
- Publication number
- OA11733A OA11733A OA1200100161A OA1200100161A OA11733A OA 11733 A OA11733 A OA 11733A OA 1200100161 A OA1200100161 A OA 1200100161A OA 1200100161 A OA1200100161 A OA 1200100161A OA 11733 A OA11733 A OA 11733A
- Authority
- OA
- OAPI
- Prior art keywords
- iodo
- benzamide
- methyl
- phenylamino
- bromo
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Seasonings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11329198P | 1998-12-22 | 1998-12-22 | |
| US16478899P | 1999-11-10 | 1999-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA11733A true OA11733A (en) | 2005-05-12 |
Family
ID=26810891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200100161A OA11733A (en) | 1998-12-22 | 1999-12-21 | Combination chemotherapy. |
Country Status (31)
| Country | Link |
|---|---|
| EP (1) | EP1140291B1 (et) |
| JP (1) | JP2002532570A (et) |
| KR (1) | KR20010099877A (et) |
| CN (1) | CN1333698A (et) |
| AP (1) | AP2001002175A0 (et) |
| AT (1) | ATE310567T1 (et) |
| AU (1) | AU2203900A (et) |
| BG (1) | BG105715A (et) |
| BR (1) | BR9916839A (et) |
| CA (1) | CA2352326A1 (et) |
| CZ (1) | CZ20012139A3 (et) |
| DE (1) | DE69928568T2 (et) |
| EA (1) | EA200100687A1 (et) |
| EE (1) | EE200100339A (et) |
| ES (1) | ES2253928T3 (et) |
| GE (1) | GEP20043172B (et) |
| HK (1) | HK1042057A1 (et) |
| HR (1) | HRP20010473A2 (et) |
| HU (1) | HUP0104844A3 (et) |
| ID (1) | ID30250A (et) |
| IL (1) | IL143939A0 (et) |
| IS (1) | IS5969A (et) |
| MA (1) | MA26768A1 (et) |
| NO (1) | NO20013099L (et) |
| NZ (1) | NZ512859A (et) |
| OA (1) | OA11733A (et) |
| PL (1) | PL348326A1 (et) |
| SK (1) | SK8712001A3 (et) |
| TR (1) | TR200101871T2 (et) |
| WO (1) | WO2000037141A1 (et) |
| YU (1) | YU45401A (et) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU2503A (sh) * | 2000-07-19 | 2006-05-25 | Warner-Lambert Company | Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina |
| AU8856201A (en) | 2000-09-01 | 2002-03-13 | Andel Inst Van | Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma |
| AU2002255852B2 (en) * | 2001-03-22 | 2006-11-09 | Van Andel Research Institute | Anthrax lethal factor inhibits tumor growth and angiogenesis |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| CZ20022216A3 (cs) * | 2001-07-02 | 2003-05-14 | Warner-Lambert Company | Kombinační chemoterapie |
| EP1676837A4 (en) * | 2003-10-08 | 2008-09-10 | Teijin Pharma Ltd | METHOD FOR PRODUCING AN AMINOPYRROLIDINE DERIVATIVE AND AN INTERMEDIATE COMPOUND |
| KR101013932B1 (ko) | 2003-10-21 | 2011-02-14 | 워너-램버트 캄파니 엘엘씨 | Ｎ-[(ｒ)-2,3-디히드록시-프로폭시]-3,4-디플루오로-2-(2-플루오로-4-요오도페닐아미노)-벤자미드 다형체 형태 |
| EP1802579B1 (en) | 2004-10-20 | 2013-11-20 | Merck Serono SA | Derivatives of 3-arylaminopyridine |
| CN1807413B (zh) * | 2005-09-28 | 2010-05-05 | 中国医学科学院医药生物技术研究所 | 咔唑磺酰胺衍生物及其制备方法 |
| ATE504565T1 (de) | 2005-10-07 | 2011-04-15 | Exelixis Inc | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
| US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
| WO2007054556A1 (de) | 2005-11-11 | 2007-05-18 | Æterna Zentaris Gmbh | Neue pyridopyrazine und deren verwendung als modulatoren von kinasen |
| EP1790342A1 (de) | 2005-11-11 | 2007-05-30 | Zentaris GmbH | Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege |
| PL2101759T3 (pl) | 2006-12-14 | 2019-05-31 | Exelixis Inc | Sposoby stosowania inhibitorów MEK |
| JP5651125B2 (ja) | 2008-12-10 | 2015-01-07 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異 |
| ES2674682T3 (es) | 2010-02-25 | 2018-07-03 | Dana-Farber Cancer Institute, Inc. | Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF |
| JP5985401B2 (ja) | 2010-03-09 | 2016-09-06 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | 第一の癌療法に対する耐性を現に有するか、または、そのような耐性を生じる患者において癌を診断および治療する方法 |
| CN103301096B (zh) * | 2012-03-14 | 2015-05-06 | 中国中化股份有限公司 | 取代二苯胺类化合物作为制备抗肿瘤药物的应用 |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| BR112015008113B1 (pt) | 2012-10-12 | 2022-05-24 | Exelixis, Inc. | Novo processo para preparar compostos para uso no tratamento de câncer |
| US10139415B2 (en) | 2013-02-27 | 2018-11-27 | Daiichi Sankyo Company, Limited | Method for predicting responsiveness to compound inhibiting MAPK signal transduction pathway |
| CN105384754B (zh) * | 2014-09-02 | 2018-04-20 | 上海科州药物研发有限公司 | 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途 |
| CN111909053B (zh) * | 2020-08-06 | 2022-12-06 | 湖北省生物农药工程研究中心 | 基于二芳胺单元的酰胺类衍生物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112248A0 (en) * | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| AU2092597A (en) * | 1996-03-07 | 1997-09-22 | Novartis Ag | Antiproliferative combinations, containing raf-targeted oligonucleotides and chemotherapeutic compounds |
| US6251943B1 (en) * | 1997-02-28 | 2001-06-26 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a MEK inhibitor |
| EP0988376A2 (en) * | 1997-03-21 | 2000-03-29 | The Board Of Regents, The University Of Texas System | Noey2 gene compositions and methods of use |
| US6002008A (en) * | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6040321A (en) * | 1997-11-12 | 2000-03-21 | Bristol-Myers Squibb Company | Aminothiazole inhibitors of cyclin dependent kinases |
| US5959097A (en) * | 1998-11-20 | 1999-09-28 | Isis Pharmaceuticals, Inc. | Antisense modulation of MEK2 expression |
-
1999
- 1999-12-21 YU YU45401A patent/YU45401A/sh unknown
- 1999-12-21 CA CA002352326A patent/CA2352326A1/en not_active Abandoned
- 1999-12-21 CZ CZ20012139A patent/CZ20012139A3/cs unknown
- 1999-12-21 BR BR9916839-1A patent/BR9916839A/pt not_active Application Discontinuation
- 1999-12-21 ES ES99966523T patent/ES2253928T3/es not_active Expired - Lifetime
- 1999-12-21 IL IL14393999A patent/IL143939A0/xx unknown
- 1999-12-21 HU HU0104844A patent/HUP0104844A3/hu unknown
- 1999-12-21 CN CN99815040A patent/CN1333698A/zh active Pending
- 1999-12-21 PL PL99348326A patent/PL348326A1/xx not_active Application Discontinuation
- 1999-12-21 TR TR2001/01871T patent/TR200101871T2/xx unknown
- 1999-12-21 WO PCT/US1999/030485 patent/WO2000037141A1/en active IP Right Grant
- 1999-12-21 AT AT99966523T patent/ATE310567T1/de not_active IP Right Cessation
- 1999-12-21 EP EP99966523A patent/EP1140291B1/en not_active Expired - Lifetime
- 1999-12-21 AU AU22039/00A patent/AU2203900A/en not_active Abandoned
- 1999-12-21 NZ NZ512859A patent/NZ512859A/en unknown
- 1999-12-21 GE GEAP19996007A patent/GEP20043172B/en unknown
- 1999-12-21 EA EA200100687A patent/EA200100687A1/ru unknown
- 1999-12-21 ID IDW00200101616A patent/ID30250A/id unknown
- 1999-12-21 KR KR1020017007874A patent/KR20010099877A/ko not_active Application Discontinuation
- 1999-12-21 JP JP2000589248A patent/JP2002532570A/ja active Pending
- 1999-12-21 SK SK871-2001A patent/SK8712001A3/sk unknown
- 1999-12-21 EE EEP200100339A patent/EE200100339A/et unknown
- 1999-12-21 AP APAP/P/2001/002175A patent/AP2001002175A0/en unknown
- 1999-12-21 DE DE69928568T patent/DE69928568T2/de not_active Expired - Fee Related
- 1999-12-21 OA OA1200100161A patent/OA11733A/en unknown
-
2001
- 2001-06-14 IS IS5969A patent/IS5969A/is unknown
- 2001-06-21 HR HR20010473A patent/HRP20010473A2/hr not_active Application Discontinuation
- 2001-06-21 NO NO20013099A patent/NO20013099L/no not_active Application Discontinuation
- 2001-07-18 BG BG105715A patent/BG105715A/xx unknown
- 2001-07-19 MA MA26275A patent/MA26768A1/fr unknown
-
2002
- 2002-05-04 HK HK02103397.1A patent/HK1042057A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| OA11733A (en) | Combination chemotherapy. | |
| AU776788C (en) | Treatment of arthritis with MEK inhibitors | |
| US6251943B1 (en) | Method of treating or preventing septic shock by administering a MEK inhibitor | |
| EP0993437B1 (en) | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors | |
| EP1140062B1 (en) | Treatment of asthma with mek inhibitors | |
| US7019033B2 (en) | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives | |
| ZA200104000B (en) | Antiviral method using MEK inhibitors. | |
| WO2000035435A1 (en) | Use of a mek inhibitor for preventing transplant rejection | |
| US20040171632A1 (en) | Combination chemotherapy | |
| MXPA01005476A (en) | Combination chemotherapy |